Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case.

Atak, Mehmet Fatih; Farabi, Banu; Akbayrak, Atiye; Kalelioglu, Mehmet Berati; Rao, Babar K

Atak, Mehmet Fatih; Farabi, Banu; Akbayrak, Atiye; Kalelioglu, Mehmet Berati; Rao, Babar K.

Afiliação

Atak MF; Dermatology Department, Tokat State Hospital, Tokat, Turkey.
Farabi B; Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.
Akbayrak A; Department of Dermatology, Gazi Osman Pasa University Hospital, Tokat, Turkey.
Kalelioglu MB; Department of Pathology, Tokat State Hospital, Tokat, Turkey.
Rao BK; Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.

J Cosmet Dermatol ; 20(8): 2387-2389, 2021 Aug.

Article em En | MEDLINE | ID: mdl-34139069

Assuntos

Pustulose Exantematosa Aguda Generalizada; Tratamento Farmacológico da COVID-19; Pustulose Exantematosa Aguda Generalizada/etiologia; Amidas; Humanos; Hidroxicloroquina/efeitos adversos; Pirazinas; SARS-CoV-2

Palavras-chave

AGEP; COVID-19; acute generalized exanthematous pustulosis; cutaneous adverse event; favipiravir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pustulose Exantematosa Aguda Generalizada / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google